Robyn M. Scherber

Hematology

7979 Wurzbach Rd
San Antonio, TX 78229

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Assessing real-world natural history of indolent systemic mastocytosis: A retrospective matched cohort study.

Assessing real-world natural history of indolent systemic mastocytosis: A retrospective matched cohort study.

Journal: The journal of allergy and clinical immunology. Global

Published: December 01, 2025

Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasms.

Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasms.

Journal: Leukemia & lymphoma

Published: June 02, 2024

Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire.

Translation, Cultural Adaptation, and Validation into Romanian of the Myeloproliferative Neoplasm Symptom Assessment Form-Total Symptom Score (MPN-SAF TSS or MPN-10) Questionnaire.

Journal: Journal of clinical medicine

Published: May 10, 2024

Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

Avapritinib versus Placebo in Indolent Systemic Mastocytosis.

Journal: NEJM evidence

Published: February 06, 2024

The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence.

The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence.

Journal: Cancer research communications

Published: August 28, 2023

Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs.

Ruxolitinib for myelofibrosis in elderly non-transplant patients: healthcare resource utilization and costs.

Journal: Journal of medical economics

Published: June 09, 2023

The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase.

The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase.

Journal: medRxiv : the preprint server for health sciences

Published: May 22, 2023

Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study.

Patient-reported outcomes of patients with myelofibrosis or essential thrombocythemia enrolled in the MOST study.

Journal: Leukemia & lymphoma

Published: October 07, 2022

Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.

Quality of life independently predicts overall survival in myelofibrosis: Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study.

Journal: British journal of haematology

Published: March 07, 2022

Trends in overall mortality among US veterans with primary myelofibrosis.

Trends in overall mortality among US veterans with primary myelofibrosis.

Journal: BMC cancer

Published: February 04, 2022

Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.

Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.

Journal: Leukemia & lymphoma

Published: October 25, 2021

Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.

Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemia.

Journal: Leukemia research

Published: October 05, 2021

Showing 1-12 of 53

Last Updated: 09/26/2026